Nordic Bioscience has a unique track record (both regulatory and scientific) coming from 15 years of experience in development of ELISA-based biochemical markers and is a world leader in developing biochemical markers based on tissue specificity. This is achieved by vigorous tissue specific target protein selection and its combination with specific pathological/enzyme specific processes. Extracellular matrix (ECM) remodelling, in which old or damaged proteins are broken down and replaced by new, intact ones, is a key process in tissue homeostasis.

Specific proteolytic activities are a prerequisite for a range of cellular functions and interactions within the extracellular matrix during remodelling.  Under pathological situations of diseases involving connective remodelling (such as fibrosis) this repair-response relationship is disturbed. This leads to excessive tissue turnover and abnormal remodelling in which the original proteins of the extracellular matrix (ECM) are degraded.

During pathological remodeling of the ECM quantifiable levels of tissue- and pathology- specific turnover products are released into the systemic circulation. These may be used as molecular serological markers of pathology. Nordic Bioscience has developed serological biochemical markers and a platform for identifying novel biochemical markers for use in drug development and identifying patients in need of treatment.